MS4A1 and myeloid sarcoma: Orrelizumab, another CD20-specific cytolytic antibody, has also been shown to be suitable for the treatment of patients with relapsed or primary progressive forms of MS(Boz et al., 2019; Sabatino et al., 2019; Fox et al., 2021).